Extinction of an instrumental response: A cognitive behavioral assay in Fmr1 knockout mice

Genes, Brain and Behavior

Volumn 13, Issue 5, 2014, Pages 451-458

  Sidorov, M S ^a   Krueger, D D ^a,b   Taylor, M ^a   Gisin, E ^a   Osterweil, E K ^a,c   Bear, M F ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Fragile X; Instrumental extinction; Intellectual disability; Lovastatin; Metabotropic glutamate receptor 5

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; METABOTROPIC RECEPTOR 5; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; FMR1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BEHAVIOR; COGNITION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; GENETIC CROSS; GENOTYPE; INSTRUMENTAL CONDITIONING; MALE; MOUSE; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REINFORCEMENT; SIGNAL TRANSDUCTION; VISUAL DISCRIMINATION; ANIMAL; C57BL MOUSE; FRAGILE X SYNDROME; GENETICS; METABOLISM; PATHOPHYSIOLOGY; VISION;

ANIMALS; COGNITION; CONDITIONING, OPERANT; EXTINCTION, PSYCHOLOGICAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; MALE; MICE; MICE, INBRED C57BL; PHENOTYPE; PREFRONTAL CORTEX; VISUAL PERCEPTION;

EID: 84904758859     PISSN: 16011848     EISSN: 1601183X     Source Type: Journal    
DOI: 10.1111/gbb.12137     Document Type: Article

References (37)

1. Bear, M.F., Huber, K.M. & Warren, S.T. (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27, 370-377.
2. Bouton, M.E. (2002) Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry 52, 976-986.
3. Chesworth, R., Brown, R.M., Kim, J.H. & Lawrence, A.J. (2013) The metabotropic glutamate 5 receptor modulates extinction and reinstatement of methamphetamine-seeking in mice. PLoS One 8, e68371.
4. Cleva, R.M., Gass, J.T., Widholm, J.J. & Olive, M.F. (2010) Glutamatergic targets for enhancing extinction learning in drug addiction. Curr Neuropharmacol 8, 394-408.
5. Cleva, R.M., Hicks, M.P., Gass, J.T., Wischerath, K.C., Plasters, E.T., Widholm, J.J. & Olive, M.F. (2011) mGluR5 positive allosteric modulation enhances extinction learning following cocaine self-administration. Behav Neurosci 125, 10-19.
6. D'Hooge, R., Nagels, G., Franck, F., Bakker, C.E., Reyniers, E., Storm, K., Kooy, R.F., Oostra, B.A., Willems, P.J. & De Deyn, P.P. (1997) Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 76, 367-376.
7. Dolen, G., Osterweil, E., Rao, B.S.S., Smith, G.B., Auerbach, B.D., Chattarji, S. & Bear, M.F. (2007) Correction of fragile X syndrome in mice. Neuron 56, 955-962.
8. Gass, J.T. & Olive, M.F. (2009) Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory. Biol Psychiatry 65, 717-720.
9. Klanker, M., Feenstra, M. & Denys, D. (2013) Dopaminergic control of cognitive flexibility in humans and animals. Front Neurosci 7, 201.
10. Koekkoek, S.K., Yamaguchi, K., Milojkovic, B.A. et al. (2005) Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome. Neuron 47, 339-352.
11. Kramvis, I., Mansvelder, H.D., Loos, M. & Meredith, R. (2013) Hyperactivity, perseveration and increased responding during attentional rule acquisition in the fragile Xmousemodel. Front Behav Neurosci 7, 172.
12. Krueger, D.D. & Bear, M.F. (2011) Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62, 411-429.
13. Krueger, D.D., Osterweil, E.K., Chen, S.P., Tye, L.D. & Bear, M.F. (2011) Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc Natl Acad Sci USA 108, 2587-2592.
14. Kufahl, P.R., Hood, L.E., Nemirovsky, N.E., Barabas, P., Halstengard, C., Villa, A., Moore, E., Watterson, L.R. & Olive, M.F. (2012) Positive allosteric modulation of mGluR5 accelerates extinction learning but not relearning following methamphetamine self-administration. Front Pharmacol 3, 194.
15. Laggerbauer, B., Ostareck, D., Keidel, E.M., Ostareck-Lederer, A. & Fischer, U. (2001) Evidence that fragile Xmental retardation protein is a negative regulator of translation. HumMol Genet 10, 329-338.
16. Levenga, J., Hayashi, S., de Vrij, F.M.S., Koekkoek, S.K., van der Linde, H.C., Nieuwenhuizen, I., Song, C., Buijsen, R.A.M., Pop, A.S., GomezMancilla, B., Nelson, D.L., Willemsen, R., Gasparini, F. & Ben, A.O. (2011) AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 42, 311-317.
17. Li, Z., Zhang, Y., Ku, L., Wilkinson, K.D., Warren, S.T. & Feng, Y. (2001) The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res 29, 2276-2283.
18. Lu, Y.M., Jia, Z., Janus, C., Henderson, J.T., Gerlai, R., Wojtowicz, J.M. & Roder, J.C. (1997) Mice lackingmetabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17, 5196-5205.
19. Michalon, A., Sidorov, M., Ballard, T.M., Ozmen, L., Spooren, W., Wettstein, J.G., Jaeschke, G., Bear, M.F. & Lindemann, L. (2012) Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74, 49-56.
20. Michalon, A., Bruns, A., Risterucci, C., Honer, M., Ballard, T.M., Ozmen, L., Jaeschke, G., Wettstein, J.G., von Kienlin, M., Kunnecke, B. & Lindemann, L. (2013) Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice. Biol Psychiatry 75, 189-197.
21. Millan, E.Z., Marchant, N.J. & McNally, G.P. (2011) Extinction of drug seeking. Behav Brain Res 217, 454-462.
22. Mineur, Y.S., Sluyter, F., de Wit, S., Oostra, B.A. & Crusio, W.E. (2002) Behavioral and neuroanatomical characterization of theFmr1 knockout mouse. Hippocampus 12, 39-46.
23. Moon, J., Beaudin, A.E., Verosky, S., Driscoll, L.L., Weiskopf, M., Levitsky, D.A., Crnic, L.S. & Strupp, B.J. (2006) Attentional dysfunction, impulsivity, and resistance to change in a mouse model of fragile X syndrome. Behav Neurosci 120, 1367-1379.
24. Oddi, D., Crusio, W.E., D'Amato, F.R. & Pietropaolo, S. (2013) Monogenic mouse models of social dysfunction: implications for autism. Behav Brain Res 251, 75-84.
25. Osterweil, E.K., Krueger, D.D., Reinhold, K. & Bear, M.F. (2010) Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 30, 15616-15627.
26. Osterweil, E.K., Chuang, S.-C., Chubykin, A.A., Sidorov, M., Bianchi, R., Wong, R.K.S. & Bear, M.F. (2013) Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77, 243-250.
27. Qin, M., Kang, J., Burlin, T.V., Jiang, C. & Smith, C.B. (2005) Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J Neurosci 25, 5087-5095.
28. Rebec, G.V. & Sun, W. (2005) Neuronal substrates of relapse to cocaine-seeking behavior: role of prefrontal cortex. J Exp Anal Behav 84, 653-666.
29. Schneider, A., Hagerman, R.J. & Hessl, D. (2009) Fragile X syndrome - from genes to cognition. Dev Disabil Res Rev 15, 333-342.
30. The Dutch-Belgian Fragile X Consortium (1994) Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78, 23-33.
31. Verkerk, A.J., Pieretti, M., Sutcliffe, J.S. et al. (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905-914.
32. Vinueza Veloz, M.F., Buijsen, R.A., Willemsen, R., Cupido, A., Bosman, L.W., Koekkoek, S.K., Potters, J.W., Oostra, B.A. & De Zeeuw, C.I. (2012) The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. Genes Brain Behav 11, 325-331.
33. De Vrij, F.M.S., Levenga, J., van der Linde, H.C., Koekkoek, S.K., De Zeeuw, C.I., Nelson, D.L., Oostra, B.A. & Willemsen, R. (2008) Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31, 127-132.
34. Yamada, T., Shinnoh, N., Taniwaki, T., Ohyagi, Y., Asahara, H., Horiuchi, I. & Kira, J. (2000) Lovastatin does not correct the accumulation of very long-chain fatty acids in tissues of adrenoleukodystrophy protein-deficient mice. J Inherit Metab Dis 23, 607-614.
35. Yan, Q.J., Asafo-Adjei, P.K., Arnold, H.M., Brown, R.E. & Bauchwitz, R.P. (2004) A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav 3, 337-359.
36. Yan, Q.J., Rammal, M., Tranfaglia, M. & Bauchwitz, R.P. (2005) Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49, 1053-1066.
37. Yu, H., Bi, Y., Ma, W., He, L., Yuan, L., Feng, J. & Xiao, R. (2010) Long-term effects of high lipid and high energy diet on serum lipid, brain fatty acid composition, and memory and learning ability in mice. Int J Dev Neurosci 28, 271-276.